comparison of effects of nebulised Furosemide, oxygen and placebo in patients with acute dyspnea transmited to hospitals by EMS

comparison of effects of nebulised Fursemide, oxygen and placebo in patients with acute dyspnea transmited to hospitals by EMS

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 300 patients. In order to randomize, the block randomization method will be used.

In this study, All patients with acute dyspnea transferred to hospitals by emergency will be enrolled. Patients will be randomly divided into 3 groups based on Blocks with size 12. The sample size for each study group is 100. A total of 300 patients will be examined. Patients and data analyzer will be blind.

All patients with acute dyspnea transferred to hospitals by emergency will be enrolled. Inclusion criteria: Patient transfer by pre-hospital emergency, patients over 18 years, . Exclusion criteria: patients over 75 years, Patients require mechanical ventilation, Loss of consciousness, Accompanied by another disease that requires treatment in the first 10 minutes of treatment with digoxin, beta-blocker, beta-agonist and calcium blocker, Need another inhalation treatment in the first 10 minutes, Need non-invasive positive pressure ventilation

Intervention group 1: In addition to routine treatment, 40 mg of inhaled furosemide will be given as a nebulizer at the scene. Intervention group 2: In addition to routine treatment, oxygen will be administered at the scene with a mechanical nebulizer. Control group: In addition to routine treatment, 10 cc of normal saline will be prescribed as a placebo at the scene.

Acute dyspnea; Percentage of oxygen saturation

Patients will be randomly assigned to tree groups by using a random number table. In order to randomize, a random block method will be used. For this purpose, we formed blocks of size 12. In each block, 4 individuals will be in intervention group 1, 4 individuals will be in intervention group 2 and 4 will be in control group. A total of 25 blocks will be considered for the study.

Clinical caregivers and patients will be unaware and blind to the type of treatment. Similar serums were used for concealment, without drug name label and only with code. Patients will be aware that they will be randomly assigned to one of three treatment groups, but will not know which treatment will be offered in that group. Patients will be placed in one of three groups using a random number table. The clinician also knows that patients will be treated in three different ways, but will not know which method will be used for each patient. The data collector, analyst, outcome assessor, and data safety and monitoring committee will collect and analyze the information based on groups 1, 2, and 3, and will not be aware of the type of treatment provided in the groups. They will be kept blind.